The authors suggest that TRPV1 could represent a new therapeutic target for IBS, and that trials of TRPV1 antagonists are warranted.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback